The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment
Leuk Lymphoma
.
2015 May;56(5):1554-5.
doi: 10.3109/10428194.2014.975701.
Epub 2014 Nov 19.
Authors
Ahmet Emre Eskazan
1
,
Teoman Soysal
Affiliation
1
Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.
PMID:
25330444
DOI:
10.3109/10428194.2014.975701
No abstract available
Publication types
Comment
MeSH terms
Cost-Benefit Analysis*
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology*
Male